Epilepsy and women's health: Family planning, bone health, menopause, and menstrual-related seizures

Mayo Clinic Proceedings

Volumn 78, Issue 4, 2003, Pages 497-506

  Liporace, Joyce ^a   D'Abreu, Anelyssa ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CONTRACEPTIVE AGENT; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VITAMIN K GROUP; ZONISAMIDE;

ADULT; ANTICONVULSANT THERAPY; BIRTH DEFECT; BLEEDING; BONE EXAMINATION; CONFERENCE PAPER; CONTRACEPTION; EDUCATION PROGRAM; EPILEPSY; FAMILY PLANNING; FEMALE; FETUS; FETUS MALFORMATION; GENDER; GENERAL PRACTICE; GENETIC COUNSELING; GYNECOLOGY; HEALTH BEHAVIOR; HUMAN; INTERNAL MEDICINE; MENOPAUSE; MENSTRUATION; NEURAL TUBE DEFECT; NEUROLOGY; NURSE; OBSTETRICS; PREGNANCY; SEIZURE; SEXUAL FUNCTION; UNITED STATES;

EID: 0037382536     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.4.497     Document Type: Conference Paper

References (91)

1. Gowers WR. Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms, and Treatment. New York, NY: William Wood & Co; 1885:255.
2. Woolley CS, Schwartzkroin PA. Hormonal effects on the brain. Epilepsia. 1998;39(suppl 8):S2-S8.
3. Backstrom T, Zetterlund B, Blom S, Romano M. Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol Scand. 1984;69:240-248.
4. Laidlaw J. Catamenial epilepsy. Lancet. 1956;2:1235-1237.
5. Duncan S, Read CL, Brodie MJ. How common is catamenial epilepsy? Epilepsia. 1993;34:827-831.
6. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38:1082-1088.
7. Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia. 1995;36:355-359.
8. Herzog AG, Friedman MN. Menstrual cycle interval and ovulation in women with localization-related epilepsy. Neurology. 2001;57:2133-2135.
9. Herzog AG. Clomiphene therapy in epileptic women with menstrual disorders. Neurology. 1988;38:432-434.
10. Klein P, Herzog AG. Hormonal effects on epilepsy in women. Epilepsia. 1998;39(suppl 8):S9-S16.
11. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures associated with medroxyprogesterone acetate: preliminary report. Neurology. 1984;34:1255-1258.
12. Herzog AG. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. Neurology. 1986;36:1607-1610.
13. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology. 1995;45:1660-1662.
14. Morrell MJ, Guldner GT. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia. 1996;37:1204-1210.
15. Morrell MJ, Sperling MR, Stecker M, Dichter MA. Sexual dysfunction in partial epilepsy: a deficit in physiologic sexual arousal. Neurology. 1994;44:243-247.
16. Demerdash A, Shaalan M, Midani A, Kamel F, Bahri M. Sexual behavior of a sample of females with epilepsy. Epilepsia. 1991;32:82-85.
17. Webber MP, Hauser WA, Ottman R, Annegers JF. Fertility in persons with epilepsy: 1935-1974. Epilepsia. 1986;27:746-752.
18. Schupf N, Ottman R. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: social and biologic influences. Epilepsia. 1994;35:750-756.
19. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol. 1990;30:892-896.
20. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA. 1986;256:238-240.
21. Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther. 1995;58:523-531.
22. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317-323.
23. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37(suppl 6):S34-S44.
24. Practice parameter: management issues for women with epilepsy (summary statement): report of the Quality of Standards Subcommittee of the American Academy of Neurology. Neurology. 1998;51:944-948.
25. Guberman A. Hormonal contraception and epilepsy. Neurology. 1999;53(suppl 1):S38-S40.
26. Haukkama M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception. 1986;33:559-565.
27. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263-272.
28. Eldon MA, Underwood BA, Randinitis EJ, Posvar EL, Sedman AJ. Lack of effect of gabapentin on the pharmacokinetics of a norethindrone acetate/ethinyl estradiol-containing oral contraceptive [abstract]. Neurology. 1993;43(4, suppl 2):A307. Abstract 579P.
29. Holdrich T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill [abstract]. Epilepsia. 1991;32(suppl 1):96.
30. Wilbur K, Ensom MH. Pharmocokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet. 2000;38:355-365.
31. Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia. 1985;26:631-635.
32. Hiilesmaa VK. Pregnancy and birth in women with epilepsy. Neurology. 1992;42(suppl 5):8-11.
33. Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for spontaneous abortion. Epilepsia. 1997;38:824-829.
34. Teramo K, Hiilesmaa V, Bardy A, Saarikoski S. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med. 1979;7:3-6.
35. Minkoff H, Schaffer RM, Delke I, Grunebaum AN. Diagnosis of intracranial hemorrhage in utero after a maternal seizure. Obstet Gynecol. 1985;65(suppl 3):22S-24S.
36. Lindhout D, Meinardi H, Meijer JW, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology. 1992;42(4, suppl 5):94-110.
37. Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology. 1982;32:1247-1254.
38. Nei M, Daly S, Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology. 1998;51:904-906.
39. Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry. 1983;46:751-755.
40. Knight AH, Rhind EG. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia. 1975;16:99-110.
41. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology. 1992;42(4, suppl 5):12-16.
42. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41:709-713.
43. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol. 1987;21:176-182.
44. Czeizel AE, Dudas I. Prevention of the first occurrence of neuraltube defects by periconceptional vitamin supplementation. N Engl J Med, 1992;327:1832-1835.
45. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-137.
46. Hernández-Dfaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608-1614.
47. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 1999;40:345-350.
48. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet. 1995;345:149-151.
49. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol. 2000;57:1422-1427.
50. Strauss RG, Bernstein R. Folic acid and dilantin antagonism in pregnancy. Obstet Gynecol. 1974;44:345-348.
51. Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr. Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug-treated epileptics. Am J Clin Nutr. 1975;28:51-58.
52. Kalter H, Warkany J. Congenital malformations (second of two parts). N Engl J Med. 1983;308:491-497.
53. Yerby MS, Leppik I. Epilepsy and the outcomes of pregnancy. J Epilepsy. 1990;3:193-199.
54. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344:1132-1138.
55. Rosa F. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 1991;324:674-677.
56. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet. 1982;2:937.
57. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects [letter]. Lancet. 1986;1:1392-1393.
58. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology. 1992;42(4, suppl 5):111-118.
59. Holmes LB, Lieberman ES. Report of first positive findings from hospital-based AED Pregnancy Registry [abstract]. Teratology. 2001;63:250. Abstract 17.
60. Oguni M, Dansky L, Andermann E, Sherwin A, Andermann F. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev. 1992;14:371-380.
61. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia. 1988; 29:459-467.
62. Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia. 1980;21:663-680.
63. GlaxoSmithKline International. Lamotrigine Pregnancy Registry: interim report 1 September 1992 through 31 March 2002. Wilmington, NC: PharmaReseach Corporation; 2002.
64. Samrén EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol. 1999;46:739-746.
65. Hanson JW, Smith DW, The fetal hydantoin syndrome. J Pediatr 1975;87:285-290.
66. Gaily E, Granstrom ML. Minor anomalies in children of mothers with epilepsy. Neurology. 1992;42(4, suppl 5):128-131.
67. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Is carbamazepine teratogenic? a prospective controlled study of 210 pregnancies. Neurology. 2001;57:321-324.
68. Meador KJ. Neurodevelopmental effects of antiepileptic drugs. Curr Neurol Neurosci Rep. 2002;2:373-378.
69. Gaily E, Granstrom ML, Hiilesmaa VK, Bardy AH. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res. 1990;5:217-222.
70. Gaily E, Kantola-Sorsa E, Granstrom ML. Intelligence of children of epileptic mothers. J Pediatr. 1988;113:677-684.
71. Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet. 2000;37:489-497.
72. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001;70:15-21.
73. Yerby M, Collins SD. Pregnancy and the mother. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol 2. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:2027-2035.
74. Omtzigt JG, Los FJ, Hagenaars AM, Stewart PA, Sachs ES, Lindhout D. Prenatal diagnosis of spina bifida aperta after firsttrimester valproate exposure. Prenat Diagn. 1992;12:893-897.
75. Wladimiroff JW, Stewart PA, Reuss A, van Swaay E, Lindhout D, Sachs ES. The role of ultrasound in the early diagnosis of fetal structural defects following maternal anticonvulsant therapy. Ultrasound Med Biol. 1988;14:657-660.
76. Luthy DA, Wardinsky T, Shurtleff DB, et al. Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally. N Engl J Med. 1991;324:662-666.
77. Medeiros YS, Calixto JB. Inhibitory effect of diphenylhydantoin on myometrium from pregnant women in vitro: a comparative study with nicardipine and trifluoperazine. Pharmacol Res. 1990;22:597-603.
78. Scher J, Hailey DM, Beard RW. The effects of diazepam on the fetus. J Obstet Gynaecol Br Commonw. 1972;79:635-638.
79. Niebyl JR, Blake DA, Freeman JM, Luff RD. Carbamazepine levels in pregnancy and lactation. Obstet Gynecol. 1979;53:139-140.
80. von Unruh GE, Froescher W, Hoffmann F, Niesen M. Valproic acid in breast milk: how much is really there? Ther Drug Monit. 1984;6:272-276.
81. Kuhnz W, Koch S, Helge H, Nau H. Primidone and phenobarbital during lactation period in epileptic women: total and free drug serum levels in nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther. 1988;11:147-154.
82. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia. 1997;38:1039-1041.
83. Ohman I, Vitols S, Luef G, Soderfeldt B, Tomson T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia. 2002;43:1157-1160.
84. Ito S. Drug therapy for breast-feeding women [published correction appears in N Engl J Med. 2000;343:13481. N Engl J Med. 2000; 343:118-126.
85. Ito S. Drug therapy for breast-feeding women [published correction appears in N Engl J Med. 2000;343:13481. N Engl J Med. 2000; 343:118-126.
86. Hahn TJ, Halstead LR. Anticonvulsant drug-induced osteomalacia: alterations in mineral metabolism and response to vitamin D3 administration. Calcif Tissue Int. 1979;27:13-18.
87. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57:445-449.
88. Liporace J, Ward S, Nei M, Schnur J, Sperling M. Metabolic bone disease in young adults (younger than 40 years) with epilepsy [abstract]. Epilepsia. 2001;42(suppl 7):154. Abstract 2.163.
89. Harden CL, Pulver MC, Ravdin L, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40:1402-1407.
90. Abassi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia. 1999;40:205-210.
91. Shaver JL, Zenk SN. Sleep disturbance in menopause. J Womens Health Gend Based Med. 2000;9:109-118.